Osteodex (alendronate/dextran/guanidine) / DexTech - LARVOL DELTA

Study of ODX (OsteoDex) in Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: DexTech Medical AB | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Study of ODX (OsteoDex) in Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: DexTech Medical AB

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) (clinicaltrials.gov) - P2 | N=55 | Completed | Sponsor: DexTech Medical AB | Unknown status ➔ Completed

Trial completion • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages. (PubMed, Invest New Drugs) - "Zoledronic acid (ZOL) was used for comparison. When bone marrow macrophages were incubated on bone slices, ODX and ZOL inhibited RANKL-stimulated bone resorption. In conclusion, ODX does not inhibit osteoclast formation but inhibits osteoclastic bone resorption by decreasing osteoclast numbers through enhanced cell death of mature osteoclasts."

Journal • Preclinical • CTSK • NFATC1 • TNFRSF11B • TNFSF11 • TRAP

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma (clinicaltrialsregister.eu) - P1/2 | N=20 | Ongoing | Sponsor: DexTech Medical AB

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology • CST3

"BioStock: DexTech tar nästa steg med OsteoDex https://t.co/D2Z842me4Q" (@CisionNews)

EFFECT OF OSTEODEX AND CATDEX COMPOUNDS ON THE PRIMARY CULTURE OF HUMAN ARTICULAR CARTILAGE CHONDROCYTES (ESOT 2021) - "We consider Osteodex to be a compound that shows encouraging results for improving the supplementation of human chondrocyte culture."

Genito-urinary Cancer • Immunology • Oncology • Osteoarthritis • Osteoporosis • Pain • Rheumatology • Solid Tumor • SOX9

Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) (clinicaltrials.gov) - P2; N=55; Active, not recruiting; Sponsor: DexTech Medical AB; Trial completion date: Oct 2020 ➔ Jun 2020; Trial primary completion date: Oct 2018 ➔ Jun 2018

Clinical • Trial completion date • Trial primary completion date